EBF2 Polyclonal Antibody, Cy5.5 Conjugated
Applications
Predicted Reactivity
| Overview | |
| Catalog # | bs-11740R-Cy5.5 |
| Product Name | EBF2 Polyclonal Antibody, Cy5.5 Conjugated |
| Applications |
IF(IHC-P)
IF(IHC-F)
IF(ICC)
|
| Predicted Reactivity | Human, Mouse, Rat, Dog, Cow, Sheep, Pig, Horse, Rabbit |
| Specifications | |
| Conjugation | Cy5.5 |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human EBF2 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 64641 |
| Swiss Prot | Q9HAK2 |
| Subcellular location | Nucleus |
| Synonyms | COE 2; COE2; Collier Olf and EBF 2; Early B cell factor 2; EBF 2; FLJ11500; Metencephalon mesencephalnon olfactory transcription factor 1; O/E 3; O/E3; OE 3; OE3; OLF 1/EBF like 3; Transcription factor COE2; COE2_HUMAN. |
| Background | Early B-cell factor 2 is a 575 amino acid protein belonging to the COE family of proteins, whose members are all helix-loop-helix transcription factors. EBF2 is a transcription factor which, in synergy with the Wnt-responsive LEF1/CTNNB1 pathway, activates the decoy receptor for RANKL, OPG, in osteoblasts. OPG, in turn, regulates osteoclast differentiation. Lack of EBF2 has been found to cause a small defect in the terminal differentiation of osteoblasts, along with reduced bone mass and an increase in osteoclasts. Localized to the nucleus, EBF2 forms a homodimer or a heterodimer with a related family member. |
| Application Dilution | |
| IF(IHC-P) | 1:50-200 |
| IF(IHC-F) | 1:50-200 |
| IF(ICC) | 1:50-200 |